Related Experiment Video

Updated: Aug 9, 2026

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

A3 adenosine receptor-mediated protection of the ischemic heart

John P Headrick1, Jason Peart

  • 1Heart Foundation Research Centre, Griffith University Gold Coast Campus, Southport, QLD 4217, Australia. j.headrick@g.edu.au

Vascular Pharmacology
|June 1, 2005
PubMed

Insights

The A3 adenosine receptor (A3AR) shows promise for treating heart attack by protecting heart tissue from damage. Activating A3AR with drugs offers therapeutic benefits with fewer side effects than other related treatments.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • The A3 adenosine receptor (A3AR) plays a role in heart attack recovery.
  • Endogenous adenosine minimally activates A3AR during ischemia, suggesting exogenous agonists could be beneficial.

Purpose of the Study:

  • To review the protective actions and signaling of A3ARs in ischemic-reperfused heart.
  • To discuss the potential of A3AR agonists as anti-ischemic therapeutics.

Main Methods:

  • Literature review of studies on A3AR in myocardial ischemia-reperfusion.
  • Analysis of evidence regarding A3AR activation and its effects on cardiac function and outcome.

Main Results:

  • A3AR activation modulates cell death and enhances contractile function in ischemic myocardium.
  • Pre- and post-ischemic treatment with A3AR agonists provides protection and triggers preconditioned states.
  • A3AR agonists show fewer side effects compared to other adenosine receptor subtypes.

Conclusions:

  • A3AR is a promising therapeutic target for anti-ischemic therapy.
  • Further research is needed to fully define the molecular basis of A3AR's protective actions across species and responses.

More Related Videos

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice08:30

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

Published on: April 19, 2011

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...